Search Results - "Moss, Kelley J."

Immunological and Safety Considerations When Selecting the Dose Formulation of a Purified Inactivated Zika Virus Vaccine (PIZV) by Acosta, Camilo J, Nordio, Francesco, Kpamegan, Eloi, Moss, Kelley J, Kumar, Pradeep, Hirata, Kazuhiro

“…We previously reported the first-in-human assessment of three doses (2, 5, and 10 µg) of purified inactivated Zika virus vaccine (PIZV or TAK-426) in the Phase…”
Get full text

A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate by Jackson, Lisa A., Rupp, Richard, Papadimitriou, Athanasia, Wallace, Derek, Raanan, Marsha, Moss, Kelley J.

“…•A low-dose formulation of Takeda’s dengue vaccine candidate (LD-TDV) was injected intradermally.•One or two doses of LD-TDV were well tolerated by…”
Get full text

Immunogenicity, safety, and efficacy of a tetravalent dengue vaccine in children and adolescents: an analysis by age group by Borja-Tabora, Charissa, Fernando, LakKumar, Lopez Medina, Eduardo, Reynales, Humberto, Rivera, Luis, Saez-Llorens, Xavier, Sirivichayakul, Chukiat, Yu, Delia, Folschweiller, Nicolas, Moss, Kelley J, Rauscher, Martina, Tricou, Vianney, Zhao, Yuan, Biswal, Shibadas

“…Dengue is an increasing threat to global health. This exploratory analysis evaluated the immunogenicity, safety, and vaccine efficacy (VE) of a live-attenuated…”
Get full text

IgG, IgM, and Nonstructural Protein 1 Response Profiles after Receipt of Tetravalent Dengue Vaccine TAK-003 in a Phase 2 Randomized Controlled Trial by Low, Jenny G, Oh, Helen M, Leo, Yee-Sin, Kalimuddin, Shirin, Wijaya, Limin, Pang, Junxiong, Lee, Tau Hong, Moss, Kelley J, Brose, Manja, Tricou, Vianney

“…The profiles of vaccine-induced dengue antibodies may differ from those produced following natural infection and could potentially interfere with the…”
Get more information

Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-up Compared With Natural Infection by Acosta, Camilo J, Diaz, Clemente, Nordio, Francesco, Han, Htay-Htay, Moss, Kelley J, Bohning, Kelly, Kumar, Pradeep, Liu, Mengya, Patel, Hetal, Pacciarini, Filippo, Mwangi, Vincent, Walter, Elke, Powell, Tim D, El Sahly, Hana M, Baldwin, Whitney R, Santangelo, Joseph, Anderson, Evan J, Dubin, Gary

“…Abstract Background We report 2-year persistence of immune response to Takeda's prophylactic purified formalin-inactivated whole Zika virus vaccine candidate…”
Get full text

Amino acid changes within the E protein hinge region that affect dengue virus type 2 infectivity and fusion by Butrapet, Siritorn, Childers, Thomas, Moss, Kelley J, Erb, Steven M, Luy, Betty E, Calvert, Amanda E, Blair, Carol D, Roehrig, John T, Huang, Claire Y.-H

“…Abstract Fifteen mutant dengue viruses were engineered and used to identify AAs in the molecular hinge of the envelope protein that are critical to viral…”
Get full text

Domain-III FG loop of the dengue virus type 2 envelope protein is important for infection of mammalian cells and Aedes aegypti mosquitoes by Erb, Steven M, Butrapet, Siritorn, Moss, Kelley J, Luy, Betty E, Childers, Thomas, Calvert, Amanda E, Silengo, Shawn J, Roehrig, John T, Huang, Claire Y.-H, Blair, Carol D

“…Abstract The FG extended loop in domain III of the dengue virus type 2 (DENV2) envelope protein is postulated to be a molecular determinant for host cell…”
Get full text